AKESO (09926.HK): FDA Issues CRL on Ivonescimab US BLA

On 16 November 2026, AKESO (09926.HK) said Summit's US filing for ivonescimab based on the HARMONi study received a complete response letter from the FDA.

NewTimeSpace News: On 16 November 2026, Akeso, Inc. (stock code: 09926) announced that it has noted the press release published by Summit Therapeutics Inc. (NASDAQ: SMMT) on 15 November 2026 regarding the Complete Response Letter (CRL) received from the US Food and Drug Administration for ivonescimab's Biologics License Application based on the HARMONi study.

The announcement was made at the request of The Stock Exchange of Hong Kong Limited under Rule 13.10 of the Listing Rules. Having made such enquiry as is reasonable in the circumstances, the Company confirmed that, save for the CRL which might have caused the unusual price movements of its shares, the Board is not aware of any reasons for the price movements, nor of any information that must be announced to avoid a false market in its securities or any inside information requiring disclosure under Part XIVA of the Securities and Futures Ordinance.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.